<style face="normal" font="default" size="100%">Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.</style>

Drupal-Biblio

17

<style face="normal" font="default" size="100%">miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.</style>